Neurol. praxi. 2019;20(3):183-189 | DOI: 10.36290/neu.2019.112

Muscular dystrophy of adult age

MUDr. Petr Ridzoň, MUDr. Kateřina Matějová, MUDr. Adéla Škvorová
Neurologická klinika 3. LF UK a FTN v Praze

Muscle dystrophies are progressive, hereditary diseases which are characterized by not fluctuating, chronic and (mostly) painless weakness of groups of muscles and their atrophies. They can manifest in childhood or in adult age. These diseases are rare with overlapping clinical pictures and similar phenotypes and their diagnostics is complicated, mostly performed in the neuromuscular centers. The most common muscular dystrophies should be recognized by each neurologist. Dystrophinopathies, myotonic dystrophies, facioscapulohumeral muscular dystrophy and limb girdle dystrophies are the most common dystrophies of adult age. Some dystrophies with characteristic phenotypes can be quite easily diagnosed (facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1), the issue of the most common dystrophies is described in this article. Not only appointment of diagnosis is important, but also – monitoring of disability of associated systems (heart, eyes, endocrine system, lungs), genetic consultations and solutions of social problems associated with the disease – this is a common care of each neurologist.

Keywords: muscular dystrophy, adult age, limb girdle muscular dystrophy, facioscapulohumeral, myotonic dystrophy, organdamage, care.

Published: June 12, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ridzoň P, Matějová K, Škvorová A. Muscular dystrophy of adult age. Neurol. praxi. 2019;20(3):183-189. doi: 10.36290/neu.2019.112.
Download citation

References

  1. Angelini C, Giaretta L, Marozzo R. An update on diagnostic options and considerations in limb-girdle dystrophies. Expert Rev Neurother 2018; 18(9): 693-703. Go to original source... Go to PubMed...
  2. Bednařík J. Nemoci kosterního svalstva Praha: Triton 2001: 470s.
  3. Bird TD. Myotonic Dystrophy Type 1 1999 Upt. 2018; dostupné na https://www.ncbi.nlm.nih.gov/books/NBK1165/.
  4. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992; 68: 799-808. Go to original source... Go to PubMed...
  5. Dalton JC, Ranum LPW, Day JW. Myotonic Dystrophy Type 2. 2006 Sep 21 In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews(R) University of Washington, Dostupné na: https://www.ncbi.nlm.nih.gov/books/NBK1466/.
  6. de Greef JC, Lemmers RJ, Camano P, Day JW, Sacconi S, Dunand M, van Engelen BG, Kiuru-Enari S, Padberg GW, Rosa AL, Desnuelle C, Spuler S, Tarnopolsky M, Venance SL, Frants RR, van der Maarel SM, Tawil R. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology. 2010; 75(17): 1548-1554. Go to original source... Go to PubMed...
  7. Harper PS. 3rd edition. Saunders; London: 2001. Myotonic Dystrophy.
  8. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day WJ, Ranum LPW. Myotonic Dystrophy Type 2 Caused by a CCTG Expansion in Intron 1 of ZNF9. Science 2001; 293: 864-867. Go to original source...
  9. Mah JK, Korngut L, Fiest KM, Dykeman J, Day LJ, Pringsheim T, Jette N. A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies. Can J Neurol Sci. 2016; 43(1): 163-177. Go to original source... Go to PubMed...
  10. van der Maarel SM, Tawil R, Tapscott SJ. Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med. 2011; 17(5): 252-258. Go to original source... Go to PubMed...
  11. Mazanec R, Mušová Z. Myotonické dystrofie. Neurol. praxi 2012; 13(4) 183-187.
  12. Meola G, Cardani R. Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism. Lochmüller H, ed. Journal of Neuromuscular Diseases. 2015; 2(Suppl 2): S59-S71. Dostupné na: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240594/ Go to original source... Go to PubMed...
  13. Meola G, Cardani R. Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta 2015; 1852(4): 594- 6 06. Go to original source... Go to PubMed...
  14. Motta J, Guilleminault C, Billingham M, Barry W, Mason J. Cardiac abnormalities in myotonic dystrophy: Electrophysiologic and histologic studies. Am J Med 1979; 67: 467-473. Go to original source... Go to PubMed...
  15. Narayanaswami P, Carter G, David W, Weiss M, Amato AA. Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies: Report of the Guideline Development Subcommittee of the AAN and AANEM Neurology. 2015; 84(16): 1720-1721. Dostupné na: https://www.aan.com/Guidelines/home/GetGuidelineContent/672. Go to original source...
  16. Pagoraro E. Hoffman EP. Limb-Girdle Muscular Dystrophy Overview, In: Gene Reviews /Internet/. Seattle: University of Washington, Seattle; 1993-2018.
  17. REaDY - REgistry of muscular DYstrophy. Dostupné na: http://ready.registry.cz.
  18. Ricker K, Koch MC, Lehmann-Horn F, Pongratz D, Otto M, Heine R, Moxley RT 3rd. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology. 1994; 44(8): 1448-1452. Go to original source... Go to PubMed...
  19. Schoser B, Timchenko L; Myotonic Dystrophies 1 and 2: Complex Diseases with Complex Mechanisms 2010 dostupné na https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874224/ Go to original source...
  20. Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy Continuum (Minneap Minn). 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders). 1916-1931. Go to original source...
  21. Statland J, Tawil R. Facioscapulohumeral muscular dystrophy Neurol Clin. 2014; 32(3): 721-728. Go to original source... Go to PubMed...
  22. Stehlíková K, Skálová D, Zídková J, Haberlová J, Voháňka S, Mazanec R, Mrázová L, Vondráček P, Ošlejšková H, Zámečník J, Honzík T, Zeman J, Magner M, Šišková D, Langová M, Gregor V, Godava M, Smolka V, Fajkusová L. Muscular dystrophies and myopathies: the spectrum of mutated genes in the Czech republic. Clin Genet. 2017; 91(3): 463-469. Go to original source... Go to PubMed...
  23. Straub V, Murphy A, Udd B. LGMD workshop study group. 229th ENMC international workshop: Limb girdle muscular dystrophies - Nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017. Neuromuscul Disord. 2018; 28: 702-710. Go to original source... Go to PubMed...
  24. Tawil R, Kissel JT, Heatwole C, Pandya S, Gronseth G, Benatar M. https://www.aanem.org/News-Express/Practice/Guideline-Released-for-Facioscapulohumeral-Muscula?feed=AANEM-News-ExpressEvidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy Neurology Jul 2015; 85(4) 357-364. Go to original source... Go to PubMed...
  25. Thornton CA. Myotonic dystrophy. Neurol Clin. 2014; 32(3): 705-719. Go to original source... Go to PubMed...
  26. Tzili LM, Brook D, Jones DH. Clinical and molecular aspects of the myotonic dystrophies: review. Muscle Nerve 2005; 32: 1-18. Go to original source...
  27. Voháňka S. Myotonická dystrofie - jednota v různosti. ČSNN 2017; 8/11(3): 255-265. Go to original source...
  28. Voháňka S, Parmová O, Mazanec R, Strenková J, Ridzoň P, Ehler E, Vávra A, Forgáč M, Junkerová J, Božovský T, Kunc P. Myotonic dystrophy in Czech Republic: data from the national registry. Journal of the Neurological Sciences 2015; 357(Suppl. 1). Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.